Moderna Inc is going to apply for emergency authorization in the U.S. and the European Union for its COVID-19 vaccine after full results from a late-stage study showed it's 94.1% efficacy with no serious safety concerns, Reuters reports.
“We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it. We expect to be playing a major part in turning around this pandemic," the company's Chief Medical Officer Tal Zaks emphasized.
As we reported earlier, Russian developers of Sputnik V urged the British-Sweden pharmaceutical AstraZeneca Company to combine its vaccine-candidate with the Russian one to increase its efficiency.
“If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” the statement said.
Meanwhile, AstraZeneca plans to provide up to 200 million doses of its coronavirus vaccine by the end of 2020, and 700 million doses of the substance by the end of the first quarter of the next year.